Drugs / CLSP-5282
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07650357 | Jul 2026 → May 2029 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma | Clasp Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Clasp Therapeutics, Inc. | Results Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026 clasptx.com ↗
Clasp Therapeutics, a clinical-stage biotechnology company advancing precision immuno-oncology with next-generation T-cell engagers (TCEs), today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting on CLSP‑5282, a TCE targeting KRas G12V − one of the most prevalent oncogenic driver mutations in solid tumors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Clasp Therapeutics, Inc. | Clasp Therapeutics Unveils First-in-Class KRas T Cell Engager CLSP-5282 at AACR 2026 clasptx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLSP-5282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07650357 ↗ |
| Route | Intravenous | “CLSP-5282 to be administered by IV infusion” NCT07650357 ↗ |